Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 11 2025
0mins
Source: Globenewswire
Clinical Developments: Tempest Therapeutics has received clearance to initiate a pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China and has been granted orphan drug designations by both the FDA and EMA for this treatment.
Financial Overview: The company reported a net loss of $7.9 million for Q2 2025, with cash reserves decreasing to $14.3 million, while also announcing cost-cutting measures and exploring strategic alternatives to enhance shareholder value.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
